Selecta is actively seeking partnerships including in-licensing and out-licensing opportunities that would be consistent with our product and business strategy.
and research collaboration opportunities exist for our Synthetic Vaccine
Particles (SVP™) programs. Areas of interest include vaccines and
immunotherapies including rare diseases, autoimmunity, allergies,
transplantation, cancer, infections, and respiratory diseases. Selecta is also looking for in-licensing opportunities that are coordinated with our Moscow, Russia offices. Selecta Russia has access to development capabilities that enable us to efficiently conduct comprehensive proof of concept studies.
Sanofi and Selecta are collaborating to develop up to three tolerogenic immunotherapies including severe food allergies and celiac disease.
Click here to learn more about the 2012 license for severe food allergies
Click here to learn more about the 2014 extension of the collaboration
Since 2011, Selecta and The Juvenile Diabetes Research Foundation (JDRF) are partnering to develop antigen-specific immunotherapies for the treatment of patients with juvenile diabetes (type 1 or insulin dependent diabetes mellitus), an autoimmune disorder. In 2014 JDRF and Sanofi awarded a grant to Selecta to validate lead candidates.
Click here to learn more about the 2011 collaboration
Genethon and Selecta joined forces in 2015 to co-develop next generation gene therapies that allow repeat dosing by preventing the immunogenicity of adeno-associated virus (AAV) vectors. The limited to 3 indications in the field of muscular dystrophies and liver diseases.
In 2011 Selecta was awarded a subcontract by Science Applications International Corporation (SAIC) to develop a targeted antigen-specific synthetic vaccine particle product for malaria. Part of a larger US Federal Government initiative to develop and commercialize novel therapeutics and vaccines for malaria, Selecta's development efforts will be funded under SAIC's prime contract (number N01.AI.05421) with the National Institutes of Allergy and Infectious Diseases' (NIAID)Division of Microbiology and Infectious Diseases (DMID), which is part of the National Institutes of Health. Click here to learn more about this collaboration.
In 2014, Selecta secured a $8.1million grant from the National Institute on Drug Abuse (NIDA), an institute within the U.S. National Institutes of Health (NIH) based on the data from Selecta Phase 1 clinical trial. The initial clinical study was funded in part by a $3 million grant from NIDA which was awarded to Selecta in 2010. These $11.1 million in grant funding from NIDA are aimed at advancing the development of a therapeutic vaccine for the treatment of smoking cessation and relapse prevention.
Since 2013 Selecta is collaborating with the Bill and Melinda Gates foundation to develop a novel dual action vaccine for the prevention of Malaria.
The Skolkovo foundation is providing non-dilutive funding for Selecta supporting the development of a therapeutic vaccine to treat human papillomavirus (HPV) associated cancers. Committed funding is covering IND enabling experiments, GLP toxicology and initial clinical studies. Read more here
For further information about Selecta and the company's partnering and collaboration opportunities, please contact email@example.com.